Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4372091 | 0.89 | FLT1 (0.43) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL4370907 | 0.88 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL4368106 | 0.88 | ALDH1A1 (0.44) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL4382198 | 0.83 | DGAT1 (0.39) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL4375641 | 0.81 | FLT1 (0.51) | ALDH1A1HTT | |
| SCHEMBL4372515 | 0.80 | DGAT1 (0.56) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL4374098 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL4371552 | 0.78 | ALDH1A1 (0.43) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL4371954 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GAAMAPTLMNAHTT | |
| SCHEMBL1206952 | 0.77 | DHODH (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101300231-B | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | claimed |
| CN-101300231-A | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | CN | claimed |
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | claimed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | claimed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | claimed |
| CN-101300231-B | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| CN-101300231-A | Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | CN | disclosed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | TPMT, BPNT1, SLC6A3 | PSEN1 4400/4885PSEN2 4559/4885APH1B 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.